Department of Endoscopy Center, Shanxi Province Cancer Hospital, Taiyuan, China.
Dis Esophagus. 2022 Dec 14;35(12). doi: 10.1093/dote/doac039.
The role of triamcinolone acetonide (TA) in the prevention of esophageal stricture is not well established. This meta-analysis aimed to evaluate its safety and efficacy for the prevention of esophageal stricture after endoscopic submucosal dissection (ESD).
A comprehensive search was performed in electronic databases including PubMed, the Cochrane Library, Embase for possible controlled studies. The primary outcomes were stenosis rate and endoscopic balloon dilatation (EBD) sessions required, and secondary outcome included complications. Random effects were used to calculate the pooled outcome. Sensitivity analysis and publication bias were conducted to verify the robustness and reliability of the results. Results: Ten studies containing 499 patients were obtained. In the pooled analysis, statistical significance was found in triamcinolone acetonide injection reduced the incidence of stenosis (OR = 0.29, 95% CI [0.11, 0.80], P < 0.05) and the number of endoscopic balloon dilation (MD = -3.33, 95% CI [-4.15, -2.50], P < 0.0001) compared with control. Triamcinolone acetonide injection therapy did not increase the risk of complications (OR = -0.77%, CI [-1.62, 0.09], P = 0.08). Subgroup analysis indicated that the single injection of triamcinolone acetonide after endoscopic submucosal dissection significantly reduced the incidence of stenosis compared with without any prophylaxis. Different concentrations and single session volume of triamcinolone acetonide reduced the incidence of stenosis. It also showed that the dose according to the size of the lesion was more effective than the fixed dose in preventing esophageal stricture. Conclusion: Triamcinolone acetonide injection can reduce the incidence of stricture formation as well as the need for EBD sessions without increasing complications.
曲安奈德(TA)在预防食管狭窄中的作用尚未得到充分证实。本荟萃分析旨在评估其在预防内镜黏膜下剥离(ESD)后食管狭窄中的安全性和有效性。
系统检索 PubMed、Cochrane 图书馆、Embase 等电子数据库,以获取可能的对照研究。主要结局指标为狭窄发生率和所需内镜球囊扩张(EBD)次数,次要结局指标包括并发症。采用随机效应模型计算汇总结局。进行敏感性分析和发表偏倚检验,以验证结果的稳健性和可靠性。
共纳入 10 项研究,包含 499 例患者。荟萃分析结果显示,曲安奈德注射组狭窄发生率(OR=0.29,95%CI[0.11,0.80],P<0.05)和 EBD 次数(MD=-3.33,95%CI[-4.15,-2.50],P<0.0001)均低于对照组。曲安奈德注射组治疗并未增加并发症风险(OR=-0.77%,95%CI[-1.62,0.09],P=0.08)。亚组分析表明,内镜黏膜下剥离术后单次注射曲安奈德可显著降低狭窄发生率,优于无任何预防措施。不同浓度和单次注射剂量的曲安奈德均可降低狭窄发生率。此外,根据病变大小给予剂量较固定剂量预防食管狭窄更为有效。
曲安奈德注射可降低狭窄发生率和 EBD 次数,同时不增加并发症。